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Abstract
A shared characteristic of tumor cells is their exacerbated growth. Consequently, tumor cells demand high rates of
phospholipid synthesis required for membrane biogenesis to support their growth. c-Fos, in addition to its AP-1
transcription factor activity, is the only protein known up to date that is capable of activating lipid synthesis in normal and
brain tumor tissue. For this latter activity, c-Fos associates to the endoplasmic reticulum (ER) through its N-terminal domain
and activates phospholipid synthesis, an event that requires it Basic Domain (BD) (aa 139–159). Fra-1, another member of
the FOS family of proteins, is over-expressed in human breast cancer cells and its BD is highly homologous to that of c-Fos
with two conservative substitutions in its basic amino acids. Consequently, herein we examined if Fra-1 and/or c-Fos
participate in growth of breast cancer cells by activating phospholipid synthesis as found previously for c-Fos in brain
tumors. We found both Fra-1 and c-Fos over-expressed in .95% of human ductal breast carcinoma biopsies examined
contrasting with the very low or undetectable levels in normal tissue. Furthermore, both proteins associate to the ER and
activate phospholipid synthesis in cultured MCF7 and MDA-MB231 breast cancer cells and in human breast cancer samples.
Stripping tumor membranes of Fra-1 and c-Fos prior to assaying their lipid synthesis capacity in vitro results in non-
activated lipid synthesis levels that are restored to their initial activated state by addition of Fra-1 and/or c-Fos to the assays.
In MDA-MB231 cells primed to proliferate, blocking Fra-1 and c-Fos with neutralizing antibodies blocks lipid-synthesis
activation and cells do not proliferate. Taken together, these results disclose the cytoplasmic activity of Fra-1 and c-Fos as
potential targets for controlling growth of breast carcinomas by decreasing the rate of membrane biogenesis required for
growth.
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Introduction
The fos and jun oncogenes are members of the family of
Immediate Early Genes (IEGs) AP-1 transcription factors that are
rapidly and transiently expressed in different cell types in response
to a myriad of stimuli, such as growth factors, neurotransmitters,
etc. [1–3]. The Fos proteins (c-Fos, Fra-1, Fra-2 and Fos-B) and
the Jun proteins (c-Jun, JunB and JunD) share homologous regions
containing a basic DNA-binding domain (BD) and a leucine
zipper dimerization motif. Jun proteins form homo- and hetero-
dimers whereas Fos proteins only form heterodimers with other
IEGs, mostly Jun proteins, thus originating the variety of AP-1
transcription factors that regulate target genes expression in
response to growth factors [1,4].
Although c-Fos was described as an AP-1 transcription factor
more than 20 years ago, the complex consequences of its induction
on cell physiology have still not been fully elucidated. It has been
proposed that, upon mitogenic stimuli, c-Fos triggers and controls
cell growth, differentiation and apoptosis by regulating key genes
[5]. However, we have shown that in addition to its nuclear AP-1
activity, c-Fos associates to the endoplasmic reticulum (ER) and
activates phospholipid synthesis as an additional response to
mitogenic stimuli [6]. This cytoplasmic activity of c-Fos has been
observed in vivo in light-stimulated retina ganglion and photore-
ceptor cells [6–9], in culture in NIH3T3 fibroblasts induced to re-
enter growth [10], in PC12 cells induced to differentiate [11,12],
in actively growing and proliferating T98G glioblastoma multi-
forme-derived cells [13,14], and in human and mouse tumors from
the Peripheral and Central Nervous Systems [15,16]. Although the
mechanism by which c-Fos associates to the ER and activates
phospholipid biosynthesis is currently not fully elucidated, it is
known that c-Fos physically associates with specific, key enzymes
of the pathway of phospholipid synthesis in the ER [17]. c-Fos/ER
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association is regulated by the phosphorylation state of c-Fos-
tyrosine residues #10 and #30 whereas its activation capacity
depends on its BD (20 amino acids spanning from 139–159)
[13,14,17].
The expression of Fra-1 (the Fos-related antigen-1), another
member of the Fos family of proteins, is encoded by the fos-like-1
gene (fosl1) is also induced by mitogenic stimuli [18,19]; its role in
cell growth is also not well understood. Fra-1-AP-1 transcriptional
activity is regulated both transcriptionally [20–22] and post-
translationally [22]. In exponentially growing cells, Fra-1 expres-
sion is elevated and it is hyper-phosphorylated on C-terminus Ser
and Thr residues [23]. These phosphorylation sites seem to play
a role both in stabilizing Fra-1 and on its AP-1 activity [22–26]. In
spite that the leucine zipper domain of Fra-1 is homologous to that
of other Fos family members, transcriptional activation studies
suggest that Fra-1 is a negative regulator of AP-1 activity [25,26].
Among the Fos family members, Fra-1 is probably the most
frequently expressed in different forms of human cancer [22,27]:
its over-expression has been reported in proliferative disorders
such as breast, lung, colon, oesophageal, brain and thyroid cancer
[22,27–38]. Fra-1 has also been shown as a feature of hyperplastic
and neoplastic breast disorders [31–33] with capacity to regulate
proliferation and invasiveness of breast cancer cells [29,30]. A
positive correlation has been found between Fra-1 expression and
an aggressive phenotype in breast invasive ductal carcinoma [34].
However, most work has focused on studying the nuclear activity
of Fra-1 in spite that its cytoplasmic over-expression has been
reported in breast, lung and thyroid cancer [31,33–35,38].
Tumor cells demand high rates of phospholipid synthesis to
support membrane biogenesis for their exacerbated growth. In
mice knock-out for c-Fos and knock-in for Fra-1 under the c-Fos
promoter, Fra-1 rescues and substitutes for growth-dependent
functions of c-Fos but not for its AP-1 activity [39], suggesting that
Fra-1 and c-Fos may substitute each other in some of their
biological functions. Herein we examined Fra-1 and c-Fos
expression in growing breast cancer cells and their capacity to
activate phospholipid synthesis. It is shown that both Fra-1 and c-
Fos are over-expressed in .95% of ductal breast carcinoma tissue
samples contrasting with very low or undetectable levels in normal
tissue. Both Fra-1 and c-Fos were found associated to the ER and
activating phospholipid synthesis in breast cancer cells in culture
and in human breast cancer tissue samples, thus disclosing this
activity of these proteins as a potential target for controlling
growth of breast carcinomas.
Materials and Methods
Ethics Statement
Freshly excised human breast tumor and matched benign
specimens were obtained from female patients with written
consent following the procedures indicated by the Research Ethics
Board of the Hospital Nacional de Clı´nicas, Universidad Nacional
de Co´rdoba, Argentina, and with the Helsinki Declaration of
1975, as revised in 1983. Samples were processed anonymously.
Patient ages ranged from 38–82 years old. All the procedures used
for this study were approved by the Ethics Committee of
CIQUIBIC-CONICET.
Cell Cultures and Extracts
MCF7 and MDA-MB231 cells (ATCC-Bethesda, MD, USA)
were grown under standard culture conditions in Dulbecco’s
modified Eagle medium (Gibco, BRL, Invitrogen, Carlsbad, CA,
USA) supplemented with 10% foetal bovine serum (FBS). After
desired confluence, growth was continued for 36 h (MCF7 cells) or
72 h (MDA-MB231 cells) –FBS to achieve quiescence. Cells re-
entered growth by addition of 10% FBS or cultures continued –
FBS, as indicated.
Cells were transfected 100 mg/ml Fra-1 or c-Fos antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), using the
BioPORTER QuickEasy Protein Delivery Kit (Sigma-Aldrich,
Saint Louis, MO, USA). Transfection efficiency .75% was
controlled using FITC-IgG antibody. AP-1 nuclear localization
signal peptide (NLSP) (American Peptide Company, Sunnyvale,
CA, USA) that blocks AP-1 nuclear import [11] was added to
cultures at 75 mM final concentration in 5 ml of medium. Control
cells received the same volume of delivery medium.
Sub-cellular Fractionation
This was as previously described [13]. Briefly, total homo-
genates (TH) (rinsed cultured cells or tissue samples) prepared in
PBS plus protease inhibitor cocktail (Sigma-Aldrich), were
processed with an Ultra-turrax homogenizer and centrifuged for
1 h at 100,0006g to separate the microsomal (MF) and
supernatant (SF) fractions. For stripping of TH, prior to
centrifugation, TH’s were made 1 M with KCl, left to stand for
10 min and centrifuged at 100,0006g for 1 h to separate into MF
and SF. MF was re-suspended in the initial volume of PBS plus
protease inhibitor cocktail.
Recombinant Proteins
His-tagged-recombinant Fra-1 (pDS56-HisFra) or c-Fos
(pDS56-HisFos) were expressed as described [40,41] and protein
concentration determined by Bradford assay.
Cell Proliferation Assays
CyQUANTH Cell Proliferation Assay Kit (Invitrogen) was used.
Electrophoresis and Immunoblot Assays
TH’s (40 mg) fractionated through sodium dodecyl-sulfate-
containing 12% polyacrylamide gels were electrotransferred as
described [14]. Blocked membranes were incubated overnight at
4uC in PBS-Tween 20 with: rabbit anti-Fra-1 monoclonal
antibody (mAb), rabbit anti-c-Fos mAb, mouse anti-PCNA mAb
(Santa Cruz Biotechnology, all diluted 1/1000) or mouse anti-a-
tubulin DM1A mAb (Sigma-Aldrich, dilution 1/5000). Washed
membranes were incubated 2 h at room temperature with
secondary goat IRDye 680LT anti-mouse or IRDye 800CW
anti-rabbit antibody (1/25000, LI-COR Bioscience, Lincoln, NE,
USA), washed and immunodetection performed using ODYSSEY
Infrared Imaging System (LI-COR Bioscience).
Phospholipid Synthesis Determination
In vitro phospholipid labeling determinations in tumors, cells and
sub-cellular fractions was as described [11] using 100ug of tumor/
cell homogenate protein. When stated, recombinant His-tagged
Fra-1 or c-Fos (1.5 ng/mg or 1.0 ng/mg of initial TH protein,
respectively) were added to assays re-suspended in 300 mM
imidazole/8 M urea; control incubates received the same volume
of vehicle.
Immunofluorescence Cell Analysis
Cells grown on acid-washed coverslips coated with poly-Lysine
(1g/ml), were treated as described [14]. Briefly, after blocking,
coverslips were incubated overnight at 4uC in blocking buffer
containing rabbit anti-Fra-1 (dilution 1/500), rabbit anti-c-Fos (1/
500), mouse anti-PCNA (1/500) and/or goat anti-calnexin (Santa
Cruz Biotechnology, dilution 1/500) antibodies, as indicated.
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Washed cells (46in 10 mM PBS, 0.1% Tween 20) were incubated
with anti-goat Alexa 546, anti-rabbit Alexa 488 and anti-mouse
Alexa 688 (dilution 1/1000, Molecular Probes, Eugene, OR,
USA) secondary antibodies for 2 h at RT. Coverslips mounted
with FluorSave (Calbiochem, San Diego, CA, USA) were
visualized with an Olympus FV1000 or Pascal 5 laser scanning
confocal microscope using Olympus (Centre Valley, PA, USA) or
Carl Zeiss (St Louis, MO, USA) software for image analysis.
Immunohistochemistry
Breast Tumor Tissue Array (BioChain Institute Inc., Hayward,
CA, USA) specimens were de-waxed and re-hydrated as described
[15] and incubated overnight at 4uC with primary antibodies
diluted in blocking buffer as follows: rabbit anti-Fra-1, rabbit anti-
c-Fos, mouse anti-PCNA and goat anti-calnexin (all 1/300)
antibodies. Anti-goat Alexa 546, anti-rabbit Alexa 488 and anti-
mouse Alexa 688 secondary antibodies were applied (1/500) and
slides mounted with FluorSave (Calbiochem, San Diego, CA,
USA). Visualization and image analysis was as described for cells.
Small Interfering RNA (siRNA) Transfection
To repress human Fra-1 or/and c-Fos, predesigned double-
stranded siRNAs (ON-TARGET plus SMART pool; Dharmacon
Inc., Lafayette, CO, USA) were used. A siCONTROL non-
targeting siRNA pool (Dharmacon Inc.) was used as a negative
control. MDA-MB231 cells were grown under standard culture
Figure 1. MDA-MB231 and MCF7 cells show abundant Fra-1 and c-Fos expression, which co-localizes with the ER marker calnexin.
Expression of Fra-1 (upper left columns), c-Fos (lower left columns) and the ER marker calnexin (middle columns) are shown in MDA-MB231 cells (A),
and MCF7 cells (B). Cells were immunostained for Fra-1 (top panels, green) or c-Fos (lower panels, green) and for calnexin (red). The top rows of each
panel show quiescent cells (–FBS) while those in the second row correspond to growing cells (+FBS). The last column of each panel is the merge
image of the previous two columns. Yellow color evidences Fra-1/ER (top panels) or c-Fos/ER (lower panels) co-localization sites. Clear co-localization
is evidenced for both Fra-1 and c-Fos with the ER marker calnexin as determined by confocal immunofluorescence analysis. (C). Fra-1 (upper panel)
and c-Fos (lower panel) content was determined by WB in total homogenate (TH) and in the microsomal (MF) and supernatant (SF) fractions obtained
after centrifuging MDA-MB231 (left panel) or MCF7 (right panel) cells at 100,0006g for 1 h. In addition, Fra-1 and c-Fos content was examined in MF
and SF obtained after stripping MF with 1M KCl prior to centrifugation. Results shown are from one representative experiment out of three
performed with essentially the same results.
doi:10.1371/journal.pone.0053211.g001
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conditions in DMEM supplemented with 10% FBS. After desired
cell density and 24 h prior to transfection, cell medium was
replaced by free serum and antibiotics medium. Then, cells were
transfected with SMART pool siRNA specific for human Fra-1,
human c-Fos, both of them, or scrambled siRNA at 25 nM
concentrations using Thermo Scientific DharmaFECT 1 trans-
fection reagent (Thermo Fisher Scientific, Lafayette, CO, USA) in
Opti-MEM I serum and antibiotics free medium following
manufacturer’s instructions. At 96 h incubation, cells were
stimulated with complete medium (DMEM supplemented with
10% FBS) and analyzed for proliferation and protein expression.
Statistical Analysis
Student’s two tailed t test of Infostat software (Universidad
Nacional de Co´rdoba, Argentina) was used.
Results
Fra-1 and c-Fos Expression is Up-regulated in the
Cytoplasm of Growing Beast Cancer Cells and Both
Proteins Co-localize with ER Markers
Fra-1 and c-Fos expression was analyzed by immunofluores-
cence and immunoblot in MDA-MB231 and MCF7 human breast
adenocarcinoma cell lines. MDA-MB231 are highly invasive,
Estrogen Receptor a negative, E-cadherin negative and Vimentin
positive cells whereas MCF7 are weakly invasive, Estrogen
Receptor a positive, E-cadherin positive and Vimentin negative
cells [28]. In quiescent MDA-MB231 (Figure 1A) or MCF7 cells
(Figure 1B) (–FBS: grown in the absence of FBS), low levels of both
Fra-1 (upper panels) and c-Fos (lower panels) were detected.
However, upon induction of cells to re-enter growth by feeding
with FBS (+FBS), a marked up-regulation of Fra-1 (upper panel)
and c-Fos (lower panel) expression was observed in both MDA-
MB231 (A) and MCF7 (B) cells.
Interestingly, in growing cells, c-Fos and Fra-1 were present
both in the nucleus and in the cytoplasm although both were more
abundant in the cytoplasm. When cells were immuno-stained for
the ER marker calnexin, the cytoplasmic fraction of both proteins
clearly co-localized with the ER marker (Figure 1 A–B, middle
columns and merged images to the right). This sub-cellular
localization was confirmed by WB after subjecting total homog-
enate (TH) from quiescent (–FBS) and growing cells (+FBS) to sub-
cellular fractionation by centrifugation at 100,0006g for 1 h to
isolate the microsomal (MF) and the supernatant (SF) fractions.
Both MDA-MB231 (Figure 1C, left panel) and MCF7 cells
(Figure 1C, right panel) clearly showed higher Fra-1 and c-Fos
immuno-reactivity in total homogenate (TH) from growing cells
(+FBS) as compared to quiescent (–FBS) cells and both proteins
were recovered in the MF. When the MF was stripped of its
associated proteins by treatment with 1M KCl, Fra-1 and c-Fos
were no longer recovered in MF but rather were recovered in the
SF (Figure 1C, last two lanes).
Figure 2. Schematic representations of c-Fos and Fra-1 and
comparison of their Basic Domains (BD). c-Fos is a 380 amino acid
(aa) protein whereas Fra-1 contains 271 aa. The BD of c-Fos spans from
aa 139 to 159 whereas that of Fra-1 spans from aa 107 to aa 127.
Comparison of both BDs shows that of the 12 basic aa that each contain
(schematized in bold letters), these are highly homologous showing
only two conservative substitutions of the basic aa that are underlined
in the scheme. c-Fos contains a C-terminal trans-activating domain
(TAD) that is not present in Fra-1.
doi:10.1371/journal.pone.0053211.g002
Figure 3. Phospholipid synthesis is activated in membranes fromMDA-MB231 andMCF7 cells containing Fra-1 or c-Fos.MDA-MB231
(A) and MCF7 (B) cells were used to prepare total homogenate (TH), microsomal fraction (MF) and the 1M KCl-stripped microsomal fraction (MF+1M
KCl), as indicated under Figure 2. These fractions and the stripped MF plus 1.5 ng of recombinant Fra-1 or 1 ng of c-Fos/mg of TH were assayed for
phospholipid synthesis capacity. Results are the mean cpm incorporated into phospholipids/mg protein 6 SD of 3 experiments performed in
triplicate. *: p,0.01.
doi:10.1371/journal.pone.0053211.g003
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Both Fra-1 and c-Fos Activate Phospholipid Synthesis in
MDA-MB231 and MCF7 Cells
We previously showed that the BD of c-Fos (amino acids 139–
159) is required to activate phospholipid synthesis [11,17].
Considering that the BD of Fra-1 and c-Fos are conserved
showing only two conservative substitutions in their BDs (see
schematic representation in Figure 2) and that both proteins co-
localize with the ER marker calnexin, we next studied if Fra-1, as
previously described for c-Fos in other cells [6–17], activates
phospholipid synthesis in actively growing cells. 32P-labeling of
phospholipids was determined in vitro using TH prepared from
quiescent and growing MDA-MB231 and MCF7 cells. TH and
the MF of growing MDA-MB231 cells (+FBS, second column)
showed a significant increase in 32P-phospholipid labeling as
compared to quiescent cells (–FBS, first column)(Figure 3A).
Furthermore, a comparable activation of 32P-phospholipid label-
Figure 4. Nuclear AP-1-Fra-1/c-Fos and cytoplasmic Fra-1/c-Fos are required at early and late stages of cell proliferation,
respectively. (A) MDA-MB231 cells were cultured+or – NLSP that blocks AP-1 nuclear import, in the presence or the absence of anti-Fra-1 or anti-c-
Fos antibodies added at the indicated times (0 h or 16 h) after FBS addition and examined for proliferation. Controls were performed that received
FITC-IgG antibody (last column). Proliferation was determined as indicated under Materials and Methods and expressed as arbitrary fluorescent units
of DNA. Results are the mean 6 SD of 3 experiments performed in quintuplicate; 10,000 cells were plated for each proliferation assay. Note that
nuclear import of Fra-1/c-Fos-AP-1 is required only during the first 16 h after FBS addition whereas cytoplasmic Fra-1/c-Fos are required at all time
points (compare column 5 with columns 6,7 or 8). (B) TH form MDA-MB231 cells cultured as in (A) were assayed for phospholipid synthesis capacity.
Results are the mean cpm incorporated into phospholipids/mg protein 6 SD of 3 experiments performed in triplicate. *: p,0.001.
doi:10.1371/journal.pone.0053211.g004
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ing was observed when recombinant Fra-1 (third column) or c-Fos
(fourth column) (1.5 or 1.0 ng/mg of TH protein, respectively)
were added to TH of quiescent (–FBS) cells. Similarly, when the
TH from growing cells (+FBS) was stripped with 1M KCl (thus
containing negligible levels of c-Fos and Fra-1 as shown in
Figure 1), 32P-phospholipid labeling decreased markedly mirroring
the levels in TH from quiescent cells. Addition of recombinant
Fra-1 or c-Fos to these stripped membranes restored 32P-
phospholipid synthesis to the initial activated levels (last two
columns). Similar results were observed with MCF7 cells
(Figure 3B). Altogether, these results show that Fra-1 is capable
of activating phospholipid synthesis to levels comparable to those
obtained with c-Fos.
Blocking Fra-1 and c-Fos Abrogates Phospholipid
Synthesis Activation and Cell Proliferation
The participation of nuclear and cytoplasmic c-Fos in driving
tumor cell proliferation and growth was examined in growing
MDA-MB231 cells cultured in the presence or the absence of an
AP-1 Nuclear Localization Sequence Peptide (NLSP) that blocks
the nuclear import of c-Fos and Fra-1 as AP-1 dimers [42].
Figure 4A shows that after culturing cells +FBS for 36 h, cell
number roughly doubled. However, as described previously [14],
Figure 5. Both Fra-1 and c-Fos are capable of sustaining cell proliferation. (A). MDA-MB231 cells non-transfected (first column), control-
transfected (second column) or transfected to block the expression of c-Fos (third column), or of Fra-1 (fourth column), or of both proteins (last
column) were examined for cell proliferation. Proliferation was determined as indicated under Materials and Methods and expressed as arbitrary
fluorescent units of DNA. Results are the mean6 SD of 3 experiments performed in sextuplicate; 10,000 cells were plated for each proliferation assay.
*: p,0.001. (B) WB determination of the expression of Fra-1 (top row), c-Fos (second row), PCNA (third row) and Tubulin used as a loading control
(bottom row) of the samples used in (A) to determine cell proliferation.
doi:10.1371/journal.pone.0053211.g005
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adding NLSP to the cultures at 0 or 6 h after priming cells to
proliferate (+FBS) blocks cell proliferation, whereas at later times
(16 h) it is no longer effective (column 5), indicating that nuclear
AP-1-c-Fos/Fra-1 is required to trigger proliferation at early
stages. By contrast, cytoplasmic c-Fos and Fra-1 are required at all
time points because blocking their activity with specific neutral-
izing antibodies delivered at any time after feeding FBS,+or –
NLSP, specifically blocks proliferation (Figure 4A, columns 6,7,8).
These results highlight the need of AP-1 to trigger the genomic
events for proliferation and growth and that of cytoplasmic Fra-1
and c-Fos to activate lipid synthesis required for membrane
biogenesis to sustain growth.
To confirm the importance of Fra-1/c-Fos-dependent phos-
pholipid synthesis activation during proliferation and growth, this
was assessed in FBS-stimulated MDA-MB231 cells cultured
+NLSP or -NLSP and transfected with c-Fos and Fra-1
neutralizing antibodies at different times. Accordingly, higher
rates of 32P-phospholipid labeling were detected in growing cells
(+FBS) when compared to quiescent cells (–FBS) (Figure 4B).
Feeding cells with NLSP at 0 h or 6 h after FBS priming,
abrogated 32P-phospholipid labeling activation, whereas primed
cells-activated levels were observed when NLSP was added at
16 h. These results further support that nuclear AP-1 is needed to
trigger the genomic events for proliferation and growth whereas
cytoplasmic Fra-1 and c-Fos are required to sustain growth.
Taking into consideration that MDA-MB231 and MCF7 cells
contain both c-Fos and Fra-1, it was deemed of interest to
determine if both proteins are required to support cell proliferation
or if one is enough and can substitute for the other. For this,
quiescent MDA-MB231 cells were transfected with siRNA against
c-Fos or against Fra-1 or both. At 96 h of transfection, cells were
induced to proliferate by the addition of FBS to the culture
medium and proliferation determined 36 h later. Figure 5A shows
that proliferation of mock-transfected cells was essentially the same
as that of non-transfected cells whereas transfection of siRNA
against either c-Fos or Fra-1 partially blocked proliferation.
However, blocking the expression of both proteins completely
blocks proliferation indicating that either c-Fos or Fra-1 can
support proliferation provided that protein expression levels are
high enough. Fig. 5B shows that treatment of cells with siRNA
effectively blocked c-Fos and Fra-1 expression as determined by
WB assays.
Malignant Human Breast Tumors Show Abundant Fra-1
and c-Fos Expression Associated to the ER and Activated
Phospholipid Synthesis
Considering the results described above, we analyzed Fra-1 and
c-Fos expression and phospholipid synthesis activation capacity in
malignant human breast tumor samples. Immunohistochemistry
assays revealed a marked over-expression of Fra-1 and c-Fos in
100% of 210 tissue samples from different human breast tumors
[invasive ductal carcinoma (n = 200), Medullary carcinoma (n = 2),
Phyliodes sarcoma (n = 2), Mucinous carcinoma (n = 2), lobular
carcinoma in situ (n = 2) and squamous cell carcinoma (n = 2)],
contrasting with the low or undetectable levels of Fra-1 and c-Fos
detected in the non-pathological samples (n = 37). Noteworthy,
both proteins were over-expressed in 95% of the tumor samples
analyzed, which also showed significant PCNA staining which
evidenced their active proliferative status. When assessing the
subcellular localization of these proteins, Fra-1 was found mainly
in the cytoplasm: 69% of tumor samples showed only cytoplasmic
Fra-1 whereas the remaining tumor samples contained both
nuclear and cytoplasmic-localized Fra-1 (31%). c-Fos was also
Figure 6. Human malignant breast carcinomas show abundant Fra-1 and c-Fos expression co-localizing with the ER marker
calnexin. Expression of Fra-1 (A), c-Fos (B), the ER marker calnexin, and the nuclear marker of proliferating cells PCNA was examined by triple
labeling in malignant human breast tumor specimens (n = 210) and non-pathological samples (n = 37). Six representative samples of invasive ductal
carcinomas from a tissue array immunostained for Fra-1 (A, green) or c-Fos (B, green), calnexin (red) and PCNA (blue) and three non-pathological
samples (bottom row) are shown for each onco-protein examined. Note that all actively proliferating cells (PCNA positive cells) show abundant Fra-1
and c-Fos expression which in all cases is observed co-localizing with the ER marker as evidenced by the yellow color of the merged, triple-labeled
images.
doi:10.1371/journal.pone.0053211.g006
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preferentially present in the cytoplasm of the tumor samples:
100% showed cytoplasmic c-Fos whereas, of these, 63% also
contained nuclear c-Fos. Remarkably, in all cases cytoplasmic Fra-
1 and c-Fos co-localized with the ER marker calnexin (Figure 6A,
B).
Figure 7A shows immunoblot experiments of 5 normal (N1 to
N5) and 8 tumor samples (T1 to T8) randomly selected from the
breast tissue collection. Fra-1 and c-Fos over-expression is clearly
observed in actively proliferating tumor samples (as evidenced by
the high levels of PCNA immuno-reactivity) as compared to their
non-pathological counterparts. Tubulin staining was used as
a loading control (Figure 7A). Subjecting tumor samples 5 and 6
to subcellular fractionation and WB confirmed that Fra-1 and c-
Fos expression is associated to MF and that this association is
reversed by 1M KCl-treatment (Figure 7B).
Fra-1 and c-Fos Activate Phospholipid Biosynthesis in
Human Breast Tumors
32P-Phospholipid labeling was assayed in vitro using fresh human
breast tumor and non-pathological samples. Figure 8A shows high
32P-phospholipid labeling in TH from all the tumor samples as
compared to the mean value from the non-pathological samples
(Figure 8A). This elevated phospholipid synthesis correlates with
the elevated content of c-Fos/Fra-1 and the highly proliferative
status of tumor cells (Figure 7A). Subcellular fractionation of
tumors 5 and 6 confirmed that the activated-32P-phospholipid
labeling capacity was preponderantly present in MF and that this
activity was abrogated when membranes were stripped with 1M
KCl (Figure 7B–C, fourth columns). Both, Fra-1 and c-Fos
activate phospholipid synthesis as the addition of either Fra-1 or c-
Fos to these stripped membranes restores phospholipid synthesis to
the initial rates observed in the untreated tumor MF (Figure 8B–
C). These results confirm data obtained with MDA-MB231 and
MCF7 cells and further support the role of Fra-1 and c-Fos as
activators of phospholipid synthesis to support membrane bio-
genesis for tumor cell growth.
Discussion
Fra-1 is a Fos family member that is over-expressed in diverse
types of human cancers including brain [37,43], lung [44],
oesophagus [36], thyroid [38], colorectal, skin, ovary, etc.
(reviewed in [24,27]). Of the four Fos family members, Fra-1 is
likely to be the most frequently expressed in different forms of
human cancer [24,27]. Several studies have shown that Fra-1
over-expression in breast tumor cell lines is associated with an
aggressive behavior of these cells [28,45]. Although only a few
reports have addressed Fra-1 over-expression in clinical tumors,
this was found in all malignant breast tissues [31,33,34].
Furthermore, in all these studies, nuclear and cytoplasmic Fra-1
was found although in many cases only nuclear-containing Fra-1
cells were considered as Fra-1-positive cells [34]. It was reasoned
that only nuclear-localized Fra-1 is important due to its
transcription factor function, disregarding the possibility of other
functions for this protein. By contrast, Song et al. [31] found that
90.2% of all breast carcinomas analyzed (n = 445) showed nuclear
and cytoplasmic Fra-1 over-expression whereas only 9.2% of the
samples (n = 41) showed only nuclear Fra-1 over-expression; of the
20 benign tumors examined, only 3 showed weak cytoplasmic
Figure 7. Fra-1 and c-Fos expression in malignant breast tumor biopsies and non-pathological samples. (A). Fra-1 (first row), c-Fos
(second row) and PCNA content was determined by WB in total homogenate prepared from 5 normal (N1 to N5) and 8 tumor samples (T1 to T8)
randomly selected from the collection of breast tissue samples. Note the abundant Fra-1, c-Fos and PCNA expression in all tumor samples contrasting
with the very low or undetectable expression levels in the non-pathological ones. Tubulin was used as a loading control (lower panel). (B) TH, MF and
SF obtained as described under Figure 2 from tumors #5 (left panel) and #6 (right panel) were examined for Fra-1 and c-Fos content. In addition,
Fra-1 and c-Fos content was examined in MF and SF obtained after stripping MF with 1M KCl prior to centrifugation. Results shown are from one
representative experiment out of three performed with essentially the same results.
doi:10.1371/journal.pone.0053211.g007
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immuno-reactivity that co-existed with the nuclear reactivity that
was present in all samples. However, a clear shift from nuclear to
a simultaneous nuclear/cytoplasmic localization of Fra-1 was
noticed in ,90% of breast carcinomas examined which led them
to conclude that a non-transcriptional function of Fra-1 remained
to be demonstrated [31].
We previously showed that over-expressed, cytoplasmic c-Fos
activates phospholipid synthesis in brain tumor cell lines and in
human brain tumors thus supporting the elevated rates of
membrane biogenesis required for the exacerbated growth of
these tumors [15]. To activate phospholipid synthesis, the basic
domain of c-Fos (aa 139–160) is required [16,17]. Furthermore,
point mutations of this conserved BD in basic amino acids #139
or #144 (K139N, R144N) has no effect on BD’s lipid synthesis
activating capacity whereas that of basic amino acid #146
(R146N) completely abolishes this activity further supporting the
importance of BD for the activation of specific enzymes in the
pathway of synthesis of lipids [17]. Consequently, considering the
results described above regarding Fra-1 cytoplasmic over-expres-
sion and the fact that Fra-1 and c-Fos share their basic domains,
we herein addressed the possibility that Fra-1 may also activate
phospholipid synthesis in growing human breast tumors. Using
breast tumor cell lines and clinical tumor samples, it is
demonstrated that this is indeed the case. Briefly, we found that
growing MDA-MB231 and MCF7 cells exhibit high rates of
phospholipid biosynthesis as compared with quiescent cells.
Furthermore, stripping membranes prepared from growing cells
of its non-integral proteins by 1M KCl-treatment resulted in
quiescent cell phospholipid synthesis rates, which was restored to
its initial activated rates by the addition of recombinant Fra-1 or c-
Fos to the assay medium. These results were mirrored when
analyzing human breast tumor samples: phospholipid synthesis
was also significantly higher in tumors as compared to normal
tissue and was significantly reduced when subjecting tumor
Figure 8. Phospholipid synthesis is activated in Fra-1 or c-Fos-containing human breast tumor biopsies as compared to non-
pathological specimens. (A) Phospholipid labeling capacity was determined in TH prepared from the 5 non-pathological (white columns) and 8
tumor specimens (black columns) shown in Figure 7. Results are the mean cpm incorporated into phospholipids/mg protein 6 SD of 2 experiments
performed in triplicate with each sample. (B and C) Black columns show the phospholipid labeling capacity (mean cpm incorporated into
phospholipids/mg TH protein 6 SD of 2 experiments performed in triplicate) of tumor samples #5 (B) and #6 (C) in TH (TTH), MF (TMF), 1M KCl-
stripped MF (TMF+1M KCl) and stripped MF plus 1.5 ng of recombinant Fra-1 or 1 ng of c-Fos/mg of TH. White columns (NTH) show the phospholipid
labeling capacity of pooled TH from the 5 non-pathological samples shown in (A). *: p,0.01.
doi:10.1371/journal.pone.0053211.g008
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samples to 1M KCl-treatment. Addition of Fra-1 or c-Fos to
stripped samples restored phospholipid synthesis activation to
initial rates. Finally, the previously shown dual function (nuclear
and cytoplasmic) of c-Fos (14,11) was also demonstrated for Fra-1
in experiments in which cells were fed NLSP at different times
after inducing them to re-enter growth. AP-1-Fra-1 and/or AP-1-
c-Fos were required to trigger proliferation only at early stages of
cell proliferation. In contrast, at later stages of cell proliferation
(16 h after priming cells), cytoplasmic Fra-1 and/or c-Fos (that
activate phospholipid biosynthesis) were necessary to sustain
proliferation. Blocking Fra-1 and c-Fos with intracellular neutral-
izing antibodies abrogated both phospholipid synthesis activation
and cell proliferation.
The cytoplasmic regulatory role of c-Fos or Fra-1 is not the only
AP-1 independent activity of an IEG. c-Jun was also shown to
protect cells from apoptosis independently of its AP-1 activity [46].
In addition, cytoplasmic p53 is capable of triggering apoptosis in
the absence of transcription [47] whereas translocation of nuclear
p21Cip1/WAF1 to the cytoplasm promotes resistance to apoptotic
stimuli [48]. Consequently in light of these results and of ours
shown herein, a new concept is emerging in which the biological
activity of these proteins results from the combination of their
nuclear and cytoplasmic activities [49]. These data may highlight
the significance of therapy based on the blockade of Fra-1 and/or
c-Fos functions in breast cancer. Therapies directed towards
blocking Fra-1 and c-Fos expression are promising moreover if it is
considered that these proteins are normally down-regulated in
normal breast cell growth but become up-regulated during, and
are causally related to, breast cancer progression.
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